ArticleBMJ open2020
Trends in acid suppressant drug prescriptions in primary care in the UK: a population-based cross-sectional study.
Article in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 51 citations in OpenAlex.
- Proton Pump Inhibitors and Gastric Cancer: A Large-Scale Propensity Score-Matched Analysis.Gut and liver · 2026Article
- Omeprazole activation of CD4+ and CD8+ T-cells through off-target covalent modification of cellular proteins.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Proton Pump Inhibitors (PPIs)-An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing.Medicina (Kaunas, Lithuania) · 2025Review
- Proton pump inhibitors and 1-year risk of adverse outcomes after discharge from internal medicine wards: an observational study in the REPOSI cohort.Internal and emergency medicine · 2025Observational
- Phylogenetic groups and extraintestinal virulence genes of inflowMicrobiology (Reading, England) · 2025Article
- Analyzing Prescribing Trends of Gastric Acid Suppressants in the UK Using Segmented Regression: Evaluating the Influence of COVID-19 (2019-2024).Healthcare (Basel, Switzerland) · 2025Article
- Prescribing practices for proton pump inhibitors among primary care physicians in England: an evaluation.BJGP open · 2025Article
- Budget Impact Analysis of Stepping Down Patients from Long-Term Inappropriate Proton Pump Inhibitor Use to Episodic Alginate Treatment: NHS England Perspective.Journal of health economics and outcomes research · 2025Article
- Article
- Rethinking chromogranin A: unveiling gastrointestinal factors beyond neuroendocrine neoplasms-a narrative review.Translational gastroenterology and hepatology · 2025Review
- Prescription trends of gastric acid suppressants and association with potential adverse events in Korea: a real-world cross-sectional study.Therapeutic advances in gastroenterology · 2025Article
- Pattern of Prescribing Proton Pump Inhibitors: Evaluating Appropriateness and Factors Contributing to Their Adverse Effect Reaction Risk.Journal of clinical medicine · 2024Article
- Role of prescribed medication in the development of iron deficiency anaemia in adults-a case-control study.BMJ open gastroenterology · 2024Article
- Omeprazole and risk of osteoarthritis: insights from a mendelian randomization study in the UK Biobank.Journal of translational medicine · 2024Article
- The combined effect of systemic antibiotics and proton pump inhibitors on Clostridioides difficile infection and recurrence.The Journal of antimicrobial chemotherapy · 2024Article
- Proton Pump Inhibitors: Rational Use and Use-Reduction - The Windsor Workshop.Digestive diseases (Basel, Switzerland) · 2024Review
- Article
- Evaluation of gastroprotectant administration in hospitalized cats in a tertiary referral hospital.Journal of feline medicine and surgery · 2023Article
- Article
- Use of proton pump inhibitors in scandinavian children and adolescents: An observational study.Frontiers in pediatrics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveTo examine proton pump inhibitor (PPI) and histamine-2 receptor antagonist (H2RA) prescribing patterns over a 29-year period by quantifying annual prevalence and prescribing intensity over time.
designPopulation-based cross-sectional study.
settingMore than 700 general practices contributing data to the UK Clinical Practice Research Datalink (CPRD).
participantsWithin a cohort of 14 242 329 patients registered in the CPRD, 3 027 383 patients were prescribed at least one PPI or H2RA from 1 January 1990 to 31 December 2018. PRIMARY AND SECONDARY OUTCOME MEASURES: Annual prescription rates were estimated by dividing the number of patients prescribed a PPI or H2RA by the total CPRD population. Change in prescribing intensity (number of prescriptions per year divided by person-years of follow-up) was calculated using negative binomial regression.
resultsFrom 1990 to 2018, 21.3% of the CPRD population was exposed to at least one acid suppressant drug. During that period, PPI prevalence increased from 0.2% to 14.2%, while H2RA prevalence remained low (range: 1.2%-3.4%). Yearly prescribing intensity to PPIs increased during the first 15 years of the study period but remained relatively constant for the remainder of the study period. In contrast, yearly prescribing intensity of H2RAs decreased from 1990 to 2009 but has begun to slightly increase over the past 5 years.
conclusionsWhile PPI prevalence has been increasing over time, its prescribing intensity has recently plateaued. Notwithstanding their efficacy, PPIs are associated with a number of adverse effects not attributed to H2RAs, whose prescribing intensity has begun to increase. Thus, H2RAs remain a valuable treatment option for individuals with gastric conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.